Abstract
Clarithromycin resistance in Helicobacter pylori has increased the incidence of eradication failure. Clarithromycin is a key drug in the current treatment regimens for H. pylori infection, and it is also used for nontuberculous mycobacteriosis (NTM). The rate of H. pylori infection in 15 patients with NTM who were on longterm clarithromycin, rifampicin, and other drug therapy wasexamined, using the [13C] urea breath test. H. pylori was detected in 5 of the 15 patients (33.3%), whichwas significantly lower than the prevalence of H. pyloriin subjects who had routine upper gastrointestinal endoscopy in Japan (P = 0.0006). Thus, H. pylori resistance to clarithromycin is suggested to be low in patients with longterm administration, and the possibility exists of a combination of clarithromycin and rifampicin as a second-line therapy for the eradiation of H. pylori.
Similar content being viewed by others
References
T Lind F Megraud P Unge E Bayerdorffer C O’Morain R Spiller et al. (1999) ArticleTitleThe MACH 2 study: role of omeprazole in eradication of Helicobacter pylori with 1 week triple therapies Gastroenterology 116 248–53 Occurrence Handle9922303
HS Youn SC Baik YK Cho HO Woo YO Ahn K Kim et al. (1998) ArticleTitleComparison of Helicobacter pylori infection between Fukuoka, Japan and Chinju, Korea Helicobacter 3 9–14 Occurrence Handle10.1046/j.1523-5378.1998.08011.x Occurrence Handle9546112
InstitutionalAuthorNameEuropean Helicobacter pylori Study Group (1997) ArticleTitleCurrent European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report Gut 41 8–13
RJ Adamek S Suerbaum B Pfaffenbach W Opferkuch (1998) ArticleTitlePrimary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole and amoxicillin: influence on treatment outcome Am J Gastroenterol 93 386–9 Occurrence Handle9517645
N Umegaki T Shimoyama D Nishiya T Suto S Fukuda A Munakata (2000) ArticleTitleClarithromycin-resistance and point mutations inthe 23S rRNA gene in Helicobacter pylori isolates from Japan J Gastroenterol Hepatol 15 906–9 Occurrence Handle10.1046/j.1440-1746.2000.02072.x Occurrence Handle11022832
A Pilotto M Franceschi M Rassu F Furlan M Scagnelli (2000) ArticleTitleIn vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin Am J Gastroenterol 95 833–4 Occurrence Handle10.1111/j.1572-0241.2000.01900.x Occurrence Handle10710100
S Fujimura S Kato T Kawamura A Watanabe (2002) ArticleTitleIn vitro activity of rifampicin against Helicobacter pylori isolated from children and adults J Antimicrob Chemother 49 541–3 Occurrence Handle10.1093/jac/49.3.541 Occurrence Handle11864956
F Perri V Festa R Clemente M Quitadamo A Andriulli (2000) ArticleTitleRifabutin-based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens Aliment. Pharmacol. Ther. 14 311–6 Occurrence Handle10.1046/j.1365-2036.2000.00719.x Occurrence Handle10735924
S Fujimura T Kawamura N Asou H Takahashi A Watanabe (2000) ArticleTitleHelicobacter pylori infection rate in patients treated with rifampicin: eradication effect of rifampicin on Helicobacter pylori (inJapanese with English abstract) Jpn J Chemother 48 839–42
K Murakami R Sato T Okimoto K Watanabe M Nasu T Fujioka et al. (2003) ArticleTitleInfluence of anti-ulcer drugs used in Japan on the result of 13C-urea breath test for the diagnosis of Helicobacter pylori infection J.Gastroenterol 38 937–41 Occurrence Handle10.1007/s00535-003-1176-x Occurrence Handle14614600
S Ohara M Kato M Asaka T Toyota (1998) ArticleTitleStudies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan J.Gastroenterol 33 6–13
M Heep M Kist S Strobel D Beck N Lehn (2000) ArticleTitleSecondary resistance among 554 isolates of Helicobacter pylori after failure of therapy Eur J Clin Microbiol Infect Dis 19 538–41 Occurrence Handle10.1007/s100960000288 Occurrence Handle10968325
InstitutionalAuthorNameAmerican Thoracic Society (1997) ArticleTitleDiagnosis and treatment of disease caused by nontuberculous mycobacteria Am J Respir Crit Care Med 156 S1–S25
M Heep D Beck E Bayerdorffer N Lehn (1999) ArticleTitleRifampin and rifabutin resistance mechanism in Helicobacter pylori Antimicrob Agents Chemother 43 1497–9 Occurrence Handle10348780
M Asaka T Kimura M Kudo H Takeda S Mitani T Miyazaki et al. (1992) ArticleTitleRelationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population Gastroenterology 102 760–6 Occurrence Handle1537513
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yokoyama, T., Kinoshita, T., Rikimaru, T. et al. Helicobacter pylori infection rate in patients with nontuberculous mycobacteriosis who are on longterm combination chemotherapy of clarithromycin and rifampicin. J Infect Chemother 11, 173–176 (2005). https://doi.org/10.1007/s10156-005-0386-y
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10156-005-0386-y